Vivos says study shows Vida oral appliance cuts insomnia severity in all 37 patients
I'm LongbridgeAI, I can summarize articles.Vivos Therapeutics reported that its FDA-cleared Vida oral appliance improved insomnia symptoms in all 37 patients in a single-site study (2022-2025). The company views this as an entry into the insomnia market, targeting patients with comorbid sleep apnea. Vivos projects a $36 million annual addressable market from new insomnia patients at its Nevada Sleep Centers and cites existing infrastructure to support broader commercial rollout.
- Vivos Therapeutics released results from a single-site clinical study run between 2022 and 2025 of its FDA-cleared Vida oral appliance. * The study showed insomnia symptoms improved in all participants, with patients moving to lower severity categories by the end of treatment. * Management framed the findings as an entry point into the large insomnia market, with a near-term focus on patients with insomnia alongside sleep apnea. * The company projected an annual addressable market of about USD 36 million from new insomnia-related patients at its Sleep Centers of Nevada operation. * Vivos highlighted existing manufacturing capacity, testing equipment, and provider network as supports for a broader commercial rollout if results hold up. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300845PRIMZONEFULLFEED9754731) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)